A Clinical Trial to Evaluate the Safety and Efficacy of an Implantable Wireless Brain-Computer Interface(BCI)System NEO in Patients With Tetraplegia

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNeuracle Medical Technology(Shanghai) Co.,Ltd.

About this trial

To evaluate the safety and efficacy of a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO in patients with tetraplegia and to provide a basis for product registration.

Through brain-computer interface alternative technology, patients can control the external equipment with brain signals to improve the patient's quality of life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age between 18 and 65 years old, no restriction on gender.

Tetraplegia caused by cervical spinal cord injury.

Score of ≤1 on either the ball grasp or water pouring tasks of the ARAT (Action Research Arm Test).

Muscle strength of finger flexors < grade 3 according to ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury).

Disqualifiers

Without the consent of the patient or the patient's legal guardian.

Presence of syringomyelia, severe neuropathic pain, or severe spasticity that limits the participant's ability to engage in training.

Requires ventilator support.

Baclofen dosage >30 mg/day.

Trial design

Design model

Single group

Treatments tested in this trial

  • NEO

    Device

    a Minimally Invasive Wireless Implantable Brain-Computer Interface (BCI) System NEO

Treatment groups

32 Participants
are divided into 1 treatment group
Group A: Treatment groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

BCI-assisted ARAT grasp response rate

At 3 months post-operation, the investigator will assess and record the subject's ARAT (Action Research Arm Test) score under BCI-assisted conditions, then compare it with the subject's baseline unassisted ARAT grasp score. The response rate will be calculated as the percentage of responders relative to the total number of participants.

Time frame
3 months post-operation
2

Adverse Events

Time frame
Immediately post-implantation, and at 3-, and 6-months post-operation.

Secondary outcomes

1

ISNCSCI Score of the Participant

The investigator completes the ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) form.

Time frame
Baseline, and at 3-, and 6-months post-operation.
2

ARAT Score for BCI-Assisted Grasping

The investigator completes the ARAT (Action Research Arm Test) scoring form.

Time frame
2-, and 6-months post-operation
3

ARAT Score

Investigators will complete the ARAT (Action Research Arm Test) Assessment Form.

Time frame
Baseline, and at 3-, and 6-months post-operation (assessed with the device powered off).
4

Investigator's Overall Device Performance Evaluation

Investigators will complete the Investigator's Overall Device Performance Evaluation Form.

Time frame
Immediately post-implantation, and at 2-, and 3-, and 6-months post-operation.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Neuracle Medical Technology(Shanghai) Co.,Ltd.

Lead sponsor

Huashan Hospital

Collaborator

Xuanwu Hospital, Beijing

Collaborator

The First Affiliated Hospital with Nanjing Medical University

Collaborator

First Affiliated Hospital of Fujian Medical University

Collaborator

Beijing Tiantan Hospital

Collaborator

Henan Provincial People's Hospital

Collaborator

West China Hospital

Collaborator

Affiliated Hospital of Nantong University

Collaborator

The General Hospital of Eastern Theater Command

Collaborator

Peking University Third Hospital

Collaborator

Xiangya Hospital of Central South University

Collaborator

Tongji Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: